There are 2789 resources available
282P - Methylthioadenosine phosphorylase (MTAP) genomic loss in ERBB2 amplified (amp) and mutated (mut) (ERBB2+) metastatic breast cancer (MBC)
Presenter: Abirami Sivapiragasam
Session: ePoster Display
248P - The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE registry
Presenter: Marissa Meegdes
Session: ePoster Display
249P - The CDK4/6 inhibitors takeover of the HR+/HER2- locally advanced to metastatic breast cancer market in the EU5: Findings from a real-world study
Presenter: Pierre-Olivier Graff
Session: ePoster Display
250P - Palbociclib: Early treatment-related neutropenia as a potential pharmacodynamic marker?
Presenter: Xenia Fernandez Sala
Session: ePoster Display
285P - Real-world outcomes associated with pyrotinib-based therapy for HER2-positive metastatic breast cancer
Presenter: Li Hao
Session: ePoster Display
286P - Outcome of patients with HER2-positive brain metastatic breast cancer: A 10-year retrospective study
Presenter: Cecile Bigot
Session: ePoster Display
287P - Burden of illness of HER2+ in metastatic breast cancer (MBC) patients: A systematic literature review (SLR)
Presenter: Gerard Vondeling
Session: ePoster Display
288P - Real-world outcomes and safety of pyrotinib in HER2-positive metastatic breast cancer (MBC) patients: A prospective cohort study
Presenter: Ting Luo
Session: ePoster Display
289P - A retrospective population-based observational study in metastatic HER2-positive breast cancer patients in Denmark previously treated with T-DM1
Presenter: Asbjørn Due
Session: ePoster Display